First clinical trial patient receives STARflo

Article

iSTAR Medical SA announced that the first patient in its European multicentre clinical trial has been successfully implanted with the company's STARflo glaucoma drainage device.

iSTAR Medical SA announced that the first patient in its European multicentre clinical trial has been successfully implanted with the company's STARflo glaucoma drainage device.

STARflo is a non-degradable implant made from iStar Medical's STAR biomaterial. It is designed to operate as a bleb-free, micro-porous drainage system to reduce intraocular pressure in patients with open-angle glaucoma by augmenting the eye's natural uveoscleral outflow.

The implantation marks the first in a study that will be conducted across Europe to evaluate the effectiveness and safety of the STARflo system in patients with open-angle glaucoma. STARflo received European CE Mark approval in 2012 and is currently available through distributors in select countries.

The implantation procedure was successfully performed at the Quinze-Vingt National Ophthalmologic University Hospital in Paris, France.

"The STARflo device provides a unique drainage mechanism for patients presenting with advanced or refractory glaucoma and fills an unmet clinical need for patients at high risk of failure following traditional filtering surgery," said Professor Christophe Baudouin, head of the Ophthalmology Department at the Quinze-Vingt National Ophthalmologic University Hospital. "The bleb-free implantation procedure and soft material of STARflo are designed to offer a sustainable reduction of intraocular pressure."

"STARflo's unique material mimics healthy eye tissue, enhances physiological draining pathways and has been designed to minimize scarring without requiring the use of anti-metabolites," added Michel Vanbrabant, CEO of iStar. "We are excited to partner with leading glaucoma experts around Europe to increase the level of scientific evidence supporting STARflo as a superior treatment option for improving long-term efficacy and reducing post-operative care for glaucoma patients."

For more information visit www.istarmed.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.